Âé¶¹ÒùÔº

July 31, 2025

New work sheds light on the survival strategies of parasite responsible for Leishmaniasis

Ilona Gdovinova, doctoral student in virology and immunology at INRS and Professor Albert Descoteaux, director of the Infectiopole and lead author of the study. Credit: INRS
× close
Ilona Gdovinova, doctoral student in virology and immunology at INRS and Professor Albert Descoteaux, director of the Infectiopole and lead author of the study. Credit: INRS

Leishmaniasis is a parasitic disease that affects up to 1 million people worldwide each year. It is caused by the protozoan Leishmania, transmitted through the bite of a sandfly. Once inside its host—human or animal—the parasite settles in immune cells called macrophages and multiplies within small bubble-like structures known as parasitophorous vacuoles.

To replicate, Leishmania needs lipids—essential molecules for many cellular functions. Contrary to previous beliefs, the amastigote form of the parasite, which multiplies in humans, does not produce its own lipids. Instead, it must extract them directly from the .

This discovery, made by the team of Professor Albert Descoteaux at Institut national de la recherche scientifique (INRS), was recently in PLOS Pathogens.

A host protein hijacked for parasitic purposes

As part of her Ph.D. research at INRS, Ilona Gdovinova uncovered a key mechanism by which Leishmania acquires a class of lipids known as sphingolipids. She demonstrated that the parasite hijacks a host macrophage protein called VAPA, which normally facilitates transport between cellular compartments.

By observing infected , the team found that VAPA accumulates around the vacuoles containing the parasite. When this protein is blocked, the vacuole can no longer expand, and the parasite stops multiplying.

"The parasite uses VAPA as a bridge to channel the lipids it needs. It even disrupts the protein's normal interactions to better exploit it," explains Ilona Gdovinova, doctoral student in virology and immunology at INRS and first author of the study.

Get free science updates with Science X Daily and Weekly Newsletters — to customize your preferences!

"This discovery highlights how finely can manipulate cellular functions to ensure their survival," she adds.

The team, based at the INRS Armand-Frappier Santé Biotechnologie Research Centre, also found that VAPA helps the parasite transport a key virulence molecule to another part of the host cell. This shows that the protein plays a crucial role in two-way exchanges between the parasite and its host.

"By identifying a critical mechanism for Leishmania's acquisition of sphingolipids, this work opens the door to new strategies to block its replication," says Professor Albert Descoteaux, director of the Infectiopole and lead author of the study.

A specialist in host-pathogen interactions and a member of the Pasteur Network, Professor Descoteaux emphasizes the importance of understanding how these pathogens replicate in humans. This knowledge is essential for developing new therapeutic or preventive approaches—especially as drug resistance spreads and remain limited.

More information: Ilona Gdovinova et al, VAPA mediates lipid exchange between Leishmania amazonensis and host macrophages, PLOS Pathogens (2025).

Journal information: PLoS Pathogens

Provided by INRS

Load comments (0)

This article has been reviewed according to Science X's and . have highlighted the following attributes while ensuring the content's credibility:

fact-checked
peer-reviewed publication
trusted source
proofread

Get Instant Summarized Text (GIST)

Leishmania parasites responsible for Leishmaniasis rely on host-derived lipids, specifically sphingolipids, for replication within macrophages. They hijack the host protein VAPA to acquire these lipids and facilitate vacuole expansion. Blocking VAPA disrupts parasite multiplication, highlighting a potential target for new therapeutic strategies against Leishmaniasis.

This summary was automatically generated using LLM.